Takita Maiko, Iwasaki Eisuke, Hatogai Ken, Kishino Ryohei, Seki Eri, Izumiya Motoko, Maeda Norio, Nakazawa Atsushi, Mizuki Akira, Handa Kan, Shimoyama Yutaka, Mukai Kiyoshi, Higuchi Hajime, Takaishi Hiromasa, Hibi Toshifumi, Tsukada Nobuhiro
Department of Internal Medicine, Saiseikai Central Hospital.
Nihon Shokakibyo Gakkai Zasshi. 2011 Jul;108(7):1263-70.
A 57-year-old man with advanced gallbladder cancer and accompanying hepatic, colonic and duodenal invasion and para-aortic lymph node metastasis was referred to our hospital. Gemcitabine plus S-1 administration was chosen. Gemcitabine was administered intravenously at a dose of 1000 mg/m(2) on days 1 and 15, and repeated every 4 weeks. S-1 was administered orally at a dose of 40 mg/m(2) b.i.d. on days 1-14. Chemotherapy was effective for the primary gallbladder tumor and lymph node metastasis. The primary tumor and metastatic lymph nodes were shown to have disappeared by a FDG-PET CT study after 10 courses of chemotherapy. Informed consent was obtained prior to performing surgery of the primary lesion. Pathological examination showed fibrosis and a small focus of residual cancer in the resected gallbladder. Complete resection was achieved as all the margins were negative. The findings suggest that gemcitabine plus S-1 treatment may be effective against advanced gallbladder cancer.
一名57岁男性，患有晚期胆囊癌，伴有肝脏、结肠和十二指肠侵犯以及主动脉旁淋巴结转移，被转诊至我院。选择了吉西他滨联合S-1治疗。吉西他滨于第1天和第15天静脉注射，剂量为1000 mg/m²，每4周重复一次。S-1于第1 - 14天口服，剂量为40 mg/m²，每日两次。化疗对原发性胆囊肿瘤和淋巴结转移有效。在10个疗程的化疗后，FDG-PET CT检查显示原发性肿瘤和转移性淋巴结已消失。在对原发性病变进行手术前获得了知情同意。病理检查显示切除的胆囊中有纤维化和小灶残留癌。由于所有切缘均为阴性，实现了完整切除。这些结果表明，吉西他滨联合S-1治疗可能对晚期胆囊癌有效。
